Sarill M

Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy; Institute of Oncology Research (IOR), Bellinzona, Switzerland.

1 paper · ORCID

ArticlePsilocybin

Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms.

Colognesi M, Gabbia D, Signor A +30

Europe PMC2026